MichaelHSilvermanMDFACP

Rheumatology • Marblehead, MA

President and Senior Clinical Development Consultant, BioStrategics Consulting Ltd

Join to view full profile

Dr. Silverman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Silverman's full profile

Already have an account?

Office
51 Intrepid Circle
Biostrategics Consulting Ltd
Marblehead, MA 01945
Phone+1 781-631-8596
Is this information wrong?

Education & Training

University of ColoradoFellowship, Rheumatology, 1976 - 1978
University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 1973 - 1976
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1973

Certifications & Licensure

MA State Medical License 1993 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Clinical Trials

Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients Start of enrollment: 2006 Jun 01
Completed
Phase 2
A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail Start of enrollment: 2006 Sep 01
Completed
Phase 2
Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients Start of enrollment: 2008 Feb 01
Completed
Phase 2
A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma Start of enrollment: 2009 Feb 01
Completed
Phase 1, Phase 2
A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1 Start of enrollment: 2009 Jul 01
Completed
Phase 1, Phase 2
A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee Start of enrollment: 2018 Nov 01
Withdrawn
Phase 2
Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure Start of enrollment: 2010 Oct 01
Completed
Phase 2
Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis Start of enrollment: 2010 Oct 01
Completed
Phase 2
Trial of CF101 to Treat Patients With Dry Eye Disease Start of enrollment: 2011 Jul 01
Completed
Phase 3
Trial of CF101 to Treat Patients With Psoriasis Start of enrollment: 2011 Jul 01
Completed
Phase 2, Phase 3
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers Start of enrollment: 2014 Jun 01
Completed
Phase 3
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers Start of enrollment: 2014 Jun 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with...
Ghamande, S.,Lin, C. C.,Cho, D. C.,Shapiro, G. I.,Kwak, E. L.,Silverman, M. H.,Tseng, Y.,Kuo, M. W.,Mach, W. B.,Hsu, S. C.,Coleman, T.,Yang, J. C.,Cheng, A. L.,Ghalib,...> ;Invest New Drugs. 2013 Nov 26
CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.
Stemmer SM Benjaminov O Medalia G Ciuraru NB Silverman MH Bar-Yehuda S Fishman S Harpaz Z Farbstein M Cohen S Patoka R Singer B Kerns WD Fishman P> ;Oncologist. 2013
Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial.
David M Akerman L Ziv M Kadurina M Gospodinov D Pavlotsky F Yankova R Kouzeva V Ramon M Silverman MH Fishman P> ;J Eur Acad Dermatol Venereol. 2012 Mar
Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information Part 1: Ethical considerations.
Ball, G., Piller, L.B., Silverman, M.H.> ;Contemp Clin Trials. 2011 Sep
Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information Part 3: Design considerations.
Ball, G., Silverman, M.H.> ;Contemp Clin Trials. 2011 Sep
Editorial: Continuous safety monitoring for randomized controlled clinical trials.
Piller, L.B., Silverman, M.H., Ball, G.> ;Contemp Clin Trials. 2011 Sep
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.
Pardanani, A., Gotlib, J.R., Jamieson, C., Cortes, J.E., Talpaz, M., Stone, R.M., Silverman, M.H., Gilliland, D.G., Shorr, J., Tefferi, A.> ;J Clin Oncol. 2011 Mar 1
Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.
Avni, I., Garzozi, H.J., Barequet, I.S., Segev, F., Varssano, D., Sartani, G., Chetrit, N., Bakshi, E., Zadok, D., Tomkins, O., Litvin, G., Jacobson, K.A., Fishman, S....> ;Ophthalmology. 2010 Jul
A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after fir...
Ghamande, S. A., Silverman, M. H., Huh, W., Behbakht, K., Ball, G., Cuasay, L., Würtz, S. O., Brunner, N., Gold, M. A.> ;Gynecol Oncol. 2008 Oct
Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial.
Silverman MH Strand V Markovits D Nahir M Reitblat T Molad Y Rosner I Rozenbaum M Mader R Adawi M Caspi D Tishler M Langevitz P Rubinow A Friedman J Green L Tanay A Oc...> ;J Rheumatol. 2008 Jan
The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis.
Bar-Yehuda S Silverman MH Kerns WD Ochaion A Cohen S Fishman P> ;Expert Opin Investig Drugs. 2007 Oct
Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees.
Dixon DO Freedman RS Herson J Hughes M Kim K Silverman MH Tangen CM> ;Clin Trials. 2006
A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial.
Berkenblit, A., Matulonis, U. A., Kroener, J. F., Dezube, B. J., Lam, G. N., Cuasay, L. C., Brünner, N., Jones, T. R., Silverman, M. H., Gold, M. A.> ;Gynecol Oncol. 2005 Oct
Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
van Troostenburg AR Clark EV Carey WD Warrington SJ Kerns WD Cohn I Silverman MH Bar-Yehuda S Fong KL Fishman P> ;Int J Clin Pharmacol Ther. 2004 Oct
Safety, tolerability and pharmacokinetics of subcutaneous A6, an 8-amino acid peptide with anti-angiogenic properties, in healthy men.
van Troostenburg AR Lee D Jones TR Dyck-Jones JA Silverman MH Lam GN Warrington SJ> ;Int J Clin Pharmacol Ther. 2004 May
Nitrous oxide sedation reduces discomfort caused by atrial defibrillation shocks.
Ujhelyi, M., Hoyt, R.H., Burns, K., Fishman, R.S., Musley, S., Silverman, M.H.> ;Pacing Clin Electrophysiol. 2004 Apr
Clinical trials in cervical intraepithelial neoplasia: balancing the need for efficacy data with patient safety.
Silverman, M.H., Hedley, M.L., Petry, K.U., Weber, J.S.> ;J Low Genit Tract Dis. 2002 Oct
Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca.
Laibovitz RA Solch S Andriano K O'Connell M Silverman MH> ;Cornea. 1993 Jul
Safety and tolerability of two percent cyclosporine (Sandimmune) ophthalmic ointment in normal volunteers.
Solch S Nadler PI Silverman MH> ;J Ocul Pharmacol. 1991 Winter
Join now to see all

Professional Memberships

American College of Physicians - ACP
Fellow